• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ambrosia app links Abbott’s FreeStyle Libre with Fitbit wearable

September 20, 2019 By Sean Whooley

Ambrosia Systems said today that it launched its LinkBlueCon application on the Fitbit and Abbott (NYSE:ABT) FreeStyle Libre smartwatch platforms for glucose monitoring.

San Fransisco-based Ambrosia’s LinkBlueCon app is designed to monitor glucose levels and receive notifications when glucose readings are outside the target range, all without the need to go to a clinic.

Ambrosia said it will make it easier to see health and activity data, such as sleep, heart rate and cardio fitness, and how they can affect glucose levels, on its platform.

BluCon technology is sold for $110 and can be used to display glucose readings from FreeStyle Libre, and FreeStyle Libre 2 sensors on Apple and Huawei 2 watches without using a phone. The NightRider BluCon is currently used in more than 100 countries on the FreeStyle Libre platforms, Ambrosia said in a news release.

Abbott’s FreeStyle Libre mobile app won FDA approval in November 2018, and the company touted data from the glucose monitor in February of this year. Frequent users of the technology lowered their time in hypoglycemia by 31% compared to infrequent scanners, while users who scanned a second time within one hour of a low glucose event lessened the likelihood of prolonged hypoglycemia by 56%.

Chicago-based Abbott also won reimbursement for the FreeStyle Libre in Ontario and Quebec last week.

Shares of ABT were up 0.4% at $83.58 per share in late-morning trading today.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, Ambrosia

IN CASE YOU MISSED IT

  • Eitan Medical lands FDA clearance for infusion pump system upgrade
  • Senseonics announces $50M from stock offering
  • BD stock up on Street-beating preliminary quarterly revenue numbers
  • Locate Bio lands FDA breakthrough nod for bone infection device
  • PerkinElmer to acquire Oxford Immunotec

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS